Aside from the independent anti-tumour effects of HER2-redirected CAR-T cells recognising and lysing HER2 positive tumour cells and the oncolytic potential of the vaccinia virus, the researchers highlighted the synergistic potential of the locally secreted bi-specific antibody expressed by EphA2-TEA-VV directing T-cells to recognise and kill EphA2-expressing tumour cells, overcoming tumour heterogeneity. The gene discussed is EPHA2; the disease is neoplasm.